However, utilization of encephalitogenic peptides derived from myelin basic protein (MBP) (e.g., MBP83-99), proteolipid protein (e.g., PLP139-154), and myelin oligodendrocyte glycoprotein (e.g., MOG1-20, MOG35-55) exhibit immunodominance and have shown promise in MS clinical trials (23, 25, 63, 64). This evidence concerns the gene MOG and myeloid sarcoma.